Mayo Clinic Hemophilia Treatment Center and 340B Program
Mayo Clinic Hemophilia Treatment Center and 340B Program Jenni Hovell, CPA, MHA Operations Manager—Mayo Clinic Midwest 340B Programs Hemophilia Alliance Spring Meeting April 27, 2015 ©2015 MFMER | slide-1 Mayo Clinic • Major Campuses in Minnesota (Rochester), Arizona (Scottsdale & Phoenix) and Florida (Jacksonville) • Mayo Clinic Health System Campuses in Minnesota, Iowa, Wisconsin, and Georgia • Personnel across all campuses • 4,100 staff physicians & scientists • 3,100 residents, fellows, & students • 52,100 Allied health staff • Patients across all campuses • 1,260,000 clinic patients • 131,000 hospital admissions • 608,000 patient hospital days ©2015 MFMER | slide-2 ©2015 MFMER | slide-3 HTC Roll-up Structure Mayo Clinic Board of Governors Midwest Executive Operating Team Midwest Specialty Care Clinical Practice Committee Department of Medicine Hematology Hemophilia Treatment Center ©2015 MFMER | slide-4 HTC Staff • Dr. Rajiv Pruthi, HTC Medical Director (since 2000) • 11 Physicians in Coagulation interest group • 3 RN Care Coordinators • Social Worker • Genetics Counselor • Physical Therapist • Medical Secretary ©2015 MFMER | slide-5 HTC History • 1971—established HTC under the direction of Drs Bowie, Gilchrist, and Hagedorn • Established an outpatient program providing replacement therapy (single-donor cryo) • Began instructing patients on home product storage, preparation, and infusion techniques • 1972—designation as an International Hemophilia Training Center • 1976—addition of a nurse care coordinator and social worker to the clinical team • 1986—began offering formal genetic counseling and DNA testing to patients • 1990—Dr. Dennis Gastineau becomes HTC co-Director with Dr. Gilchrist • 1991—first annual Minnesota Hemophilia Camp • 1995—made it policy to recommend recombinant-derived factor as first choice for all factor replacement therapy patients • 2000—Dr. Rajiv Pruthi named HTC Medical Director • 2006—340B program started ©2015 MFMER | slide-6 HTC Patients • 264 total bleeding disorder patients • 87 Hemophilia A • 24 Hemophilia B • 100 vonWillebrand Disease • 26 Other factor deficiencies • 27 Other bleeding disorders • 57% male, 43% female • 21% pediatrics ©2015 MFMER | slide-7 HTC Patient Support Services • Patient education weekend • School in-services • Self-infusion classes • Women’s retreat • Patient transportation • Quality projects to benefit patient care • Support of the Hemophilia Foundation of Minnesota/Dakotas ©2015 MFMER | slide-8 HTC 340B Program • Started in 2006 • Used contract pharmacy arrangement to service patients • Maintained a very small patient group on service • Bringing services in-house to our Mayo Specialty Pharmacy • Potential to grow patients on service ©2015 MFMER | slide-9 340B at Mayo Clinic • Many different Covered Entity types • Comprehensive Hemophilia Treatment Center • Ryan White Part B Grantee • Disproportionate Share Hospital • Critical Access Hospital • Sole Community Hospital • Entities across the Midwest • Minnesota (MCHS sites and Rochester) • Wisconsin (MCHS sites) ©2015 MFMER | slide-10 340B Operations Manager Role • Fall 2013 asked for an Operations Manager for HTC 340B • Spring 2014 Business Plan for all Midwest 340B developed • Midwest 340B Operations Manager hired June 2014 • Responsibilities • 50% Midwest Subcommittee • 25% HTC • 25% HIV ©2015 MFMER | slide-11 340B Oversight Subcommittee ©2015 MFMER | slide-12 Authorizing Official Role • CAH, SCH, DSH have requirement that Authorizing Official is C-level or VP • HTC and HIV Authorizing Official was Chair of the Legal Department • Wanted someone closer to the program • Granted Designation of Signing Authority to our Midwest 340B Medical Director for Certification of 340B Programs on Rochester campus ©2015 MFMER | slide-13 Questions ©2015 MFMER | slide-14
© Copyright 2024